К вопросу о потенциальных рисках канцерогенности фототерапии у больных псориазом

Обложка


Цитировать

Полный текст

Аннотация

В статье представлены данные литературы по оценке риска канцерогенного действия многокурсового применения методов фототерапии: ПУВА-терапии и УФБ-311 у больных псориазом. Проведен анализ частоты встречаемости злокачественных новообразований кожи (ПКР, БКР, злокачественной меланомы кожи) среди больных псориазом разных популяционных групп с учетом кумулятивных доз облучения и количества процедур.

Об авторах

А. А. Кубанов

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Автор, ответственный за переписку.
Email: noemail@neicon.ru
Россия

М. Б. Жилова

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: zhilova@cnikvi.ru
Россия

Список литературы

  1. Tessman J.W., Isaacs S.T., Hearst J.E. Photochemistry of the furan-side 8-methoxypsoralen-thymidine monoadduct inside the DNA helix. Conversion to diadduct and to pyroneside monoadduct. Biochemistry 1985; 24: 1669-1676.
  2. Neuner P., Charvat B., Knobler R., Kirnbauer R., Schwarz A., Luger T.A., Schwarz T. Cytokine release by peripheral blood mononuclear cells is affected by 8-methoxypsoralen plus UV-A. Photochem Photobiol 1994; 59: 182-188.
  3. Johnson R., Staiano-Coico L., Austin L., Cardinale I., Nabeya-Tsukifuji R., Krueger J.G. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996; 63: 566-571.
  4. Weichenthal M., Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed 2005; 21: 260-266.
  5. Schwarz T., Luger T.A. Effect of UV irradiation on epidermal cell cytokine production. J Photochem Photobiol B Biol 1989; 4: 1-13.
  6. Kripke M.L., Cox P.A., Alas L.G., Yarosh D.B. Pyrimidine dimers in DNA initiate systemic immunosuppression in UVB-irradiated mice. Proc Natl Acad Sci USA 1992; 89: 7516-7520.
  7. Lebwohl M., Martinez J., Weber P., De Luca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32: 469-471.
  8. Ibbotson S.H., Farr P.M. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999; 113: 346-350.
  9. Shahtmejster I.Ja., Pisarenko M.F., Vladimirov V.V. i dr. Otdalennye rezul'taty PUVA-terapii u bol'nyh psoriazom. Vestnik dermatologii i venerologii 1982; 12: 7-9. [Шахтмейстер И.Я., Писаренко М.Ф., Владимиров В.В. и др. Отдаленные результаты ПУВА-терапии у больных псориазом. Вестник дерматологии и венерологии 1982; 12: 7-9].
  10. Akovbjan V.A. Obosnovanie ogranichitel'nogo rezhima FHT psoriaza v uslovijah jekologicheskoj insoljacii. Vestnik dermatologii i venerologii 1987, 7: 40-42. [Аковбян В.А. Обоснование ограничительного режима ФХТ псориаза в условиях экологической инсоляции. Вестник дерматологии и венерологии 1987; 7: 40-42].
  11. Zavadskij V.N., EseninA.A. Mnozhestvennyj ploskokletochnyj rak kozhi u bol'nogo psoriaticheskoj jeriterodermiej. Vestnik dermatologii i venerologii 1982; 2: 65. [Завадский В.Н., Есенин А.А. Множественный плоскоклеточный рак кожи у больного псориатической эритеродермией. Вестник дерматологии и венерологии 1982; 2: 65].
  12. Marzeeva G.I., Trofimova L.Ja., Kirsanova M.M. Jeffektivnost' fotohimioterapii pri psoriaticheskoj jeritrodermii. Vestnik dermatologii i venerologii 1982; 6: 8-12. [Марзеева Г.И., Трофимова Л.Я., Кирсанова М.М. Эффективность фотохимиотерапии при псориатической эритродермии. Вестник дерматологии и венерологии 1982; 6: 8-12].
  13. Hapilova V.I., Trofimova L.Ja., Bol'shakova G.M. Materialy k otdalennym rezul'tatam lechenija bol'nyh psoriazom. Vestnik dermatologii i venerologii1990; 5: 12-13. [Хапилова В.И., Трофимова Л.Я., Большакова Г.М. Материалы к отдаленным результатам лечения больных псориазом. Вестник дерматологии и венерологии 1990; 5: 12-13].
  14. Molochkov V.A., Kuncevich Zh.S. Sluchaj razvitija gigantskoj keratoakantomy posle PUVA-terapii. Klinicheskaja dermatologija i venerologija 2003; 4: 20-21. [Молочков В.А., Кунцевич Ж.С. Случай развития гигантской кератоакантомы после ПУВА-терапии. Клиническая дерматология и венерология 2003; 4: 20-21].
  15. Stern R.S., Laird N., Melski J., Parrish J.A., Fitzpatrick T.B., Bleich H.L. Cutaneous squamouscell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-1161.
  16. Stern R.S., Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-124.
  17. Stern R.S. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990; 322: 1093-1097.
  18. Stern R.S., Lunder E.J. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Archives Of Dermatology 1998 Dec; Vol. 134 (12), pp. 1582-5.
  19. Stern R.S., Liebman E.J., Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of non-melanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284.
  20. Stern R.S. PUVA Follow-Up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-761.
  21. Stern R.S., Bagheri S., Nichols K. et al. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002; 47: 33-39.
  22. Nijsten T.E., Stern R.S. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 644-650.
  23. Katz K.A., Marcil I., Stern R.S. et al. Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen+ ultraviolet a light-treated psoriasis patients. J Invest Dermatol 2002; 118: 1038-1043.
  24. Honigsmann H., Wolff K., Gschnait F. et al. Keratoses and nonmelanoma skin tumors in longterm photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3: 406-414.
  25. Henseler T., Christophers E. Risk of skin tumors in psoralen- and ultraviolet A-treated patients. Natl Cancer Inst Monogr 1984; 66: 217-219.
  26. Henseler T., Christopher E., Honigsmann H. et al. Skin tumors in the European PUVA study. J Am Acad Dermatol 1987; 16: 108-111.
  27. Cox N.H., Jones S.K., Downey D.J. et al. Cutaneous and ocular side-effectsof oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol 1987; 116: 145-152.
  28. Bruynzeel I., Bergman W., Hartevelt H.M. et al. "High single-dose" European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
  29. Lindeloèf B., Sigurgeirsson B., Tegner E., Larkoè O., Johannesson A., Berne B., Ljunggren B., Andersson T., Molin L., Nylanderlundqvist E., Emtestam L. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141: 108-112.
  30. Hannuksela-Svahn A., Pukkala E., Koulu L., Jansen C.T., Karvonen J. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 1999; 1: 694-696.
  31. BruynzeelI I., Bergman W., Hartevelt H.M. et al. ‘High single-dose’ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55.
  32. Lassus A., Reunala T., Idänpää-Heikkilä J et al. PUVA treatment andskin cancer: a follow-up study. Acta Derm Venereol (Stockh) 1981; 61: 141.
  33. Lindskov R. Skin carcinomas and treatment with photochemotherapy. Acta Derm Venereol (Stockh) 1983; 63: 223-226.
  34. Ros A.M., Wennersten G., Lagerholm B. et al. Long-term photochemotherapy for psoriasis: a histopathological and clinical follow-up study with special emphasis on tumour incidence and behavior of pigmented lesions. Acta Derm Venereol (Stockh) 1983; 63: 215-221.
  35. Reshad H., Challoner F., Pollock D.J. et al. Cutaneous carcinoma in psoriatic patients treated with PUVA. Br J Dermatol 1984; 110: 299-305.
  36. Eskelinen A., Halme K., Lassus A. et al. Risk of cutaneous carcinoma in psoriatic patients treated with PUVA. Photodermatol 1985; 2: 10-14.
  37. Torinuki W., Tagami H. Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen, or both therapies. A 10-year follow up study. J Am Acad Dermatol 1988; 18: 1278-1281.
  38. Tanew A., Honigsmann H., Ortel B. et al. Nonmelanoma skin tumors in long-term photochemotherapy treatment of psoriasis. An 8-year followup study. J Am Acad Dermatol 1986; 15: 960-965.
  39. Abdullah A.N., Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy - a 10-year follow-up study. Clin Exp Dermatol 1989; 14: 421-424.
  40. BruynzeelI I., Bergman W., Hartevelt H.M. et al. ‘High single-dose’ European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49-55. 145.
  41. Lindelof B., Sigurgeirsson B., Tegner E. et al. Comparison of the carcinogenic potential of tri-oxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992; 128: 1341-1344.
  42. Lever L.R., Farr P.M. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215-219.
  43. Mc Kenna K.E., Patterson C.C., Handley J. et al. Cutaneous neoplasia following PUVA therapy for psoriasis. Br J Dermatol 1996; 134: 639-642.
  44. Gritiyarangsan P., Sindhavananda J., Rungrairatanaroj P. et al. Cutaneous carcinoma and PUVA lentigines in Thai patients treated with oral PUVA. Photodermatol Photoimmunol Photomed 1995; 11: 174-177.
  45. Maier H., Schemper M., Ortel B. et al. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996; 193: 185-191.
  46. Chuang T.Y., Heinrich L.A., Schultz M.D. et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173-177.
  47. Stern R.S. PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012 Apr; 66 (4): 553-62.
  48. Gupta A.K., Stern R.S., Swanson N.A., Anderson T.F. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. A case report and the experience of the PUVA follow-up study. J Am Acad Dermatol 1988; 19: 67-76.
  49. Stern R.S., Nichols K.T., Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997; 336: 1041-1045.
  50. Chen Y.J., Wu C.Y., Chen T.J. et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011; 65: 84-91.
  51. Hannuksela-Svahn A., Pukkala E., Laara E. et al. Psoriasis, its treatment, and cancer in a cohort of Finnish Patients. J Invest Dermatol 2000; 114: 587-590.
  52. Frentz G., Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999 Feb; 140 (2): 237-42.
  53. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E. et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999; 141: 497-501.
  54. Ji J., Shu X., Sundquist K., Sundquist J., Hemminki K. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer. 2009 May 5; 100 (9): 1499-502.
  55. Patel R.V., Clark L.N., Lebwohl M., Weinberg J.M. Treatments for psoriasis and the risk of malignancy. // J. Am. Acad. Dermatol. 2009 Jun; 60 (6): 1001-17.
  56. Whiteman D.C., Parsons P.G., Green А. P53 Expression and risk factors for cutaneous melanoma: A case-control study. Int. J. Cancer 1998; 77, 843-848.
  57. Pasker-de Jong P.C., Wielink G., Valk P.G., Wilt G.J. Treatment with UV-B for psoriasis and nonmelanoma skin cancer: a systematic review of the literature. Arch Dermatol. 1999 Jul; 135 (7): 834-40.
  58. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005 May; 44 (5): 355-60.
  59. Osmancevic A., Gillstedt M., Wennberg A.M., Larkö O. The Risk of Skin Cancer in Psoriasis Patients Treated with UVB Therapy. Acta Derm Venereol. 2014 Jul; 94 (4): 425-30.
  60. Weischer M., Blum A., Eberhard F., Rocken M., Berneburg M. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-374.
  61. Man I., Crombie I.K., Dawe R.S. et al. The pho-tocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data. Br J Dermatol 2005; 152: 755-757.
  62. Black R.J., Gavin A.T. Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data. Br J Dermatol 2006; 154: 566-567.
  63. Hearn R.M., Kerr A.C., Rahim K.F., Ferguson J., Dawe R.S. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008 Sep; 159 (4): 931-5.
  64. Lim J.L., Stern R.S. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124: 505-513.
  65. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62: 114-135.
  66. Weischer M., Blum A., Eberhard F. et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm. Venereol 2004; 84: 370-374.
  67. Ibbotson S.H., Bilsland D., Cox N.H., Dawe R.S., Diffey B., Edwards C. et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151: 283-297.
  68. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation.Nature 2008, 454: 436-444.
  69. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010, 20: 65-71.
  70. Schmidlin K., Spoerri A., Egger M., Zwahlen M., Stuck A., Clough-Gorr K. Cancer, a disease of aging - part 1. Swiss Med Wkly 2012; 142: 0.
  71. Schmidlin K., Spoerri A., Egger M., Zwahlen M., Stuck A., Clough-Gorr K. Cancer, a disease of aging - part 2. Swiss Med Wkly 2012; 142: 0.
  72. Green A., Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer 1990; 46: 356-361.
  73. Nestor M.S., Zarraga M.B. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J Clin Aesthet Dermatol 2012; 5: 20-24.
  74. Weinstock M.A. The epidemic of squamous cell carcinoma. JAMA 1989; 262: 2138-2140.
  75. Leonardi-Bee J., Ellison T., Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: Systematic review and Meta-analysis. Arch Dermatol 2012; 148: 939-946.
  76. El-Gabalawy H., Guenther L.C., Bernstein C.N. Epidemiology of immunemediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 2010, 85 (Imid): 2-10.
  77. Margolis D., Bilker W., Hennessy S., Vittorio C., Santanna J., Strom B.L: The risk of malignancy associated with psoriasis. Arch Dermatol 2001, 137: 778-783.
  78. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-2764.
  79. Pouplard C., Brenaut E., Horreau C., Barnetche T., Misery L., Richard M., Aractingi S., Aubin F., Cribier B., Joly P., Jullien D., Le-Maître M., Ortonne J.-P., Paul C. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013, 27 (Suppl 3): 36-46.
  80. Richard M., Barnetche T., Horreau C., Brenaut E., Pouplard C., Aractingi S., Aubin F., Cribier B., Joly P., Jullien D., Le-Maître M., Misery L., Ortonne J.-P., Paul C. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidencebased recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013, 27 (Suppl 3): 2-11.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Кубанов А.А., Жилова М.Б., 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах